| European Case Law Identifier: | ECLI:EP:BA:2015:T132911.20151119 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 19 November 2015 | ||||||||
| Case number: | T 1329/11 | ||||||||
| Application number: | 05005356.0 | ||||||||
| IPC class: | G01N 33/68 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | The use of BNP-type peptides and ANP-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload | ||||||||
| Applicant name: | F. Hoffmann-La Roche AG Roche Diagnostics GmbH |
||||||||
| Opponent name: | B.R.A.H.M.S GmbH | ||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Oral submission by accompanying person (refused) Sufficiency of disclosure - (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t111329eu1.html
Date retrieved: 17 May 2021